glp-1 agonist fda approval Pharmacovigilance Assessment of Compounded Receptor Agonists: Insights From the Adverse Event Reporting System Trends in the Development of

While NZ doesnt yet fund metformin for MS, the MACSiMiSE-BRAIN trial overseas is exploring its neuroprotective potential in progressive MS

A study published in August 2024 found a higher risk of NAION among patients prescribed semaglutide compared to individuals using non-GLP-1 receptor agonist medications, with 17 cases occurring in the semaglutide group versus six in the comparison group

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

September 3, 2025: Almost 500 New Plaintiffs Join Mounjaro Lawsuit Eli Lillys renowned type 2 diabetes drug, Mounjaro, is the subject of hundreds of lawsuits filed by patients who experienced severe side effects

Overall, these results indicate GLP-1RAs can influence a number of proteinopathies across disease models, although more understanding is required to determine when in the course of disease proteostasis can be modulated to bring about reduced neuronal loss and clinical benefit

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease